Holen Sie sich die Stockscreener-App
235.54
0.06%
0.14
Handel nachbörslich:
235.54
Schlusskurs vom Vortag:
$235.40
Offen:
$234.68
24-Stunden-Volumen:
468.12K
Relative Volume:
0.35
Marktkapitalisierung:
$32.85B
Einnahmen:
$2.12B
Nettoeinkommen (Verlust:
$-309.19M
KGV:
-103.12
EPS:
-2.2841
Netto-Cashflow:
$93.57M
1W Leistung:
+4.46%
1M Leistung:
-1.27%
6M Leistung:
+37.05%
1J Leistung:
+45.05%
1-Tages-Spanne:
$232.69
$236.37
1-Wochen-Bereich:
$223.98
$237.04
52-Wochen-Spanne:
$125.38
$246.90
Natera Inc Stock (NTRA) Company Profile
Firmenname
Natera Inc
Sektor
Branche
Telefon
650-249-9090
Adresse
13011 MCCALLEN PASS, AUSTIN, CA
Vergleichen Sie NTRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
235.54 | 32.83B | 2.12B | -309.19M | 93.57M | -2.2841 |
|
TMO
Thermo Fisher Scientific Inc
|
579.12 | 217.89B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
231.47 | 163.05B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
688.18 | 54.48B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
138.32 | 39.22B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
226.02 | 38.34B | 15.90B | 1.28B | 2.21B | 7.2842 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-10-27 | Hochstufung | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-08 | Fortgesetzt | Craig Hallum | Buy |
| 2024-02-20 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-11-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Eingeleitet | Stephens | Overweight |
| 2022-03-08 | Eingeleitet | Goldman | Buy |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-09-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-09-17 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-05-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-10-05 | Eingeleitet | JP Morgan | Neutral |
| 2018-07-05 | Bestätigt | Piper Jaffray | Overweight |
| 2017-08-07 | Bestätigt | Morgan Stanley | Overweight |
| 2016-11-10 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-23 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-11 | Bestätigt | The Benchmark Company | Buy |
| 2016-04-19 | Eingeleitet | The Benchmark Company | Buy |
| 2015-09-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2015-08-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2015-07-27 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2015-07-27 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-07-27 | Eingeleitet | Wedbush | Neutral |
Alle ansehen
Natera Inc Aktie (NTRA) Neueste Nachrichten
3 Reasons We’re Fans of Natera (NTRA) - Barchart.com
3 Reasons We're Fans of Natera (NTRA) - Finviz
J.P. Morgan Lifts Natera, Inc. (NTRA) Target on Signatera Momentum - Finviz
Natera co-founder Sheena Jonathan sells $338913 in stock - Investing.com India
Natera (NTRA): Revisiting Valuation After New JAMA Oncology Data on Signatera’s Colorectal Cancer Benefit - simplywall.st
Natera (NASDAQ:NTRA) Price Target Raised to $285.00 - MarketBeat
Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference - marketscreener.com
Will Natera Inc. stock outperform tech sector in 2025July 2025 Analyst Calls & Real-Time Volume Analysis Alerts - ulpravda.ru
How Natera Inc. stock performs in stagflationMarket Weekly Review & Precise Entry and Exit Recommendations - ulpravda.ru
Zevenbergen Capital Investments LLC Sells 11,417 Shares of Natera, Inc. $NTRA - MarketBeat
Natera (NTRA): Assessing Valuation After a Multi‑Year Share Price Surge - Yahoo Finance
Natera, Inc. $NTRA Shares Bought by Orion Porfolio Solutions LLC - MarketBeat
Did Strong New Signatera ctDNA Data Just Shift Natera’s (NTRA) Investment Narrative? - simplywall.st
How Investors Are Reacting To Natera (NTRA) Trial Data Showing Signatera’s 40% Risk Reduction In CRC - Yahoo Finance
Dir Sheena Files To Sell 4,500 Of Natera Inc [NTRA] - TradingView — Track All Markets
Can Natera Inc. stock beat analyst upgradesJuly 2025 Snapshot & Weekly High Return Opportunities - DonanımHaber
Is Natera’s 425.8% Three Year Surge Still Supported by Its Growth Story in 2025? - simplywall.st
Is Natera Inc. stock a safe buy before earningsQuarterly Profit Summary & Weekly High Conviction Trade Ideas - Улправда
Profit Recap: Will Natera Inc. stock outperform tech sector in 20252025 Biggest Moves & Growth Focused Entry Point Reports - Улправда
NTRA: Natera's Phase III Study Highlights Celecoxib's Efficacy i - GuruFocus
Study shows celecoxib improves survival in certain colorectal cancer patients - Investing.com India
Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer - New Castle News
Is Natera Inc. stock attractive after correctionJuly 2025 Opening Moves & Weekly Chart Analysis and Guides - Улправда
Thrivent Financial for Lutherans Cuts Stake in Natera, Inc. $NTRA - MarketBeat
Assenagon Asset Management S.A. Purchases 80,684 Shares of Natera, Inc. $NTRA - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Guardant Health (GH), Natera (NTRA) - The Globe and Mail
Natera (NTRA) director and co-founder discloses stock gift and sales - Stock Titan
Dir Sheena Sells 3,070 ($696.9K) Of Natera Inc [NTRA] - TradingView — Track All Markets
Natera’s Signatera Test Gains Validation in Key Breast Cancer Study - AD HOC NEWS
Dir Sheena Files To Sell 9,210 Of Natera Inc [NTRA] - TradingView — Track All Markets
Natera, Inc.'s (NASDAQ:NTRA) Business Is Trailing The Industry But Its Shares Aren't - 富途牛牛
Solomon Moshkevich Sells 4,692 Shares of Natera (NASDAQ:NTRA) Stock - MarketBeat
Insider Selling: Natera (NASDAQ:NTRA) Director Sells 48,419 Shares of Stock - MarketBeat
Officer Moshkevich Acquires 17,684 Of Natera Inc [NTRA] - TradingView — Track All Markets
Dir Rosenman Sells 48,419 ($11M) Of Natera Inc [NTRA] - TradingView — Track All Markets
NATERA INC : JEFFERIES RAISES TARGET PRICE TO $275 FROM $230 - 富途牛牛
Natera’s cancer test improves risk assessment in breast cancer patients By Investing.com - Investing.com Nigeria
Natera’s cancer test improves risk assessment in breast cancer patients - Investing.com
Natera, Inc. $NTRA Shares Bought by New England Research & Management Inc. - MarketBeat
Natera (NASDAQ: NTRA) I-SPY 2 study ties Signatera ctDNA status to 3-year DRFS, recurrence risk - Stock Titan
NeoGenomics (NEO): Assessing Valuation After Legal Win Over Natera and New Oncology Data Releases - simplywall.st
Jefferies raises Natera stock price target to $275 on oncology growth - Investing.com Nigeria
Barclays Raises Natera (NTRA) Price Target to $270 | NTRA Stock News - GuruFocus
NTRA: JP Morgan Raises Price Target to $260 with Overweight Rati - GuruFocus
Natera (NASDAQ:NTRA) Given New $260.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Natera dismisses appeal in patent case against NeoGenomics By Investing.com - Investing.com Nigeria
Natera dismisses appeal in patent case against NeoGenomics - Investing.com India
NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litig - pharmiweb.com
NeoGenomics Says Natera Withdraws Appeal in Patent Case - marketscreener.com
Neogenomics announces that Natera has voluntarily withdrawn its appeal in ongoing RaDaR patent litigation - marketscreener.com
Neogenomics Announces That Natera Has Voluntarily Withdrawn Its Appeal In Ongoing RaDaR Patent Litigation - TradingView — Track All Markets
Finanzdaten der Natera Inc-Aktie (NTRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.18%
0.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):